EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications

Bhanu Singh iD, Doris Zane iD, Jim Hartke iD

Toxicologic Pathology · 2026-07 · 54 (5) · 397-400

DOI: 10.1177/01926233261446894 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 12.05.2026. Verfasst von Bhanu Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: Sarcoma, Injection Site Reaction. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The two-year rodent carcinogenicity bioassay, often using the subcutaneous (SC) route for parenterally administered drugs, is a regulatory standard for evaluating carcinogenic potential. However, repeated SC injections of nongenotoxic agents or implantation of inert materials frequently induce injection-site sarcomas in rodents due to a species-specific response to chronic inflammation. This contrasts with humans, who rarely develop such tumors at injection sites, highlighting the limited relevance of these rodent findings for human risk. Extensive literature documents that rodents are uniquely susceptible to developing injection-site sarcomas following chronic local irritation and exaggerated fibroblastic proliferation responses. Marketed drugs, including pegvisomant and insulin glargine, have caused injection-site sarcomas in rodent studies but pose no corresponding risk to humans. These findings are noted in drug labeling but do not restrict marketing. Given the species-specific nature of this phenomenon and the practical challenges of dosing in long-term rodent studies, SC route of administration should be avoided for rodent carcinogenicity studies whenever feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaInjection Site ReactionAnimalsHumansCarcinogenicity TestsInjections, SubcutaneousRatsSpecies SpecificityRodentiaRisk Assessment

Stichwörter der Autor:innen

human risk assessmentinjection-site sarcomasrodent carcinogenicity bioassayspecies-specific tumorigenesissubcutaneous administration

Autor:innen und Institutionen

  • Gilead Sciences, Inc., Foster City, California, USA.

ORCID-Profile: Bhanu Singh, Doris Zane, Jim Hartke

Zitieren

APA

Singh, B., Zane, D., & Hartke, J. (2026). Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications. Toxicologic Pathology, 54(5), 397-400. https://doi.org/10.1177/01926233261446894

Vancouver

Singh B, Zane D, Hartke J. Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications. Toxicologic Pathology. 2026;54(5):397-400. doi:10.1177/01926233261446894

BibTeX
@article{Singh2026,
  author = {Singh, Bhanu and Zane, Doris and Hartke, Jim},
  title = {Injection-Site Sarcomas in Rodent Carcinogenicity Studies: Human Relevance and Labeling Implications},
  journal = {Toxicologic Pathology},
  year = {2026},
  volume = {54},
  number = {5},
  pages = {397--400},
  doi = {10.1177/01926233261446894}
}
Kostenlos starten →